Back to the drawing board for Lykos' MDMA therapy
Fuente:
Wiley Open Access
Salvato in:
| Autore principale: | |
|---|---|
| Natura: | Artículo Open Access |
| Pubblicazione: |
Wiley
2024
|
| Soggetti: | |
| Accesso online: | |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
| _version_ | 1867013964954599425 |
|---|---|
| author | Alison Knopf |
| author_facet | Alison Knopf Alison Knopf |
| collection | Wiley Open Access |
| contents | Back to the drawing board for Lykos' MDMA therapy Alison Knopf The Brown University Child & Adolescent Psychopharmacology Update The Food and Drug Administration (FDA) did not accept the application of Lykos Therapeutics for MDMA as a treatment for post‐traumatic stress disorder (PTSD). In a letter dated Aug. 9 and released by Lykos Therapeutics, the for‐profit arm of the Multidisciplinary Association for Psychedelic Studies (MAPS), the company stated that it is disappointed in the FDA response, but that it intends to pursue the goal of approval. This announcement was followed by the retraction of three peer‐reviewed studies on Aug. 9 as well. The FDA did not completely reject the idea of ever approving MDMA, but asked Lykos for more information. 10.1002/cpu30905 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| doi_str_mv | 10.1002/cpu30905 |
| format | Artículo Open Access |
| id | wiley_oa_10_1002_cpu30905 |
| institution | Wiley Open Access |
| license_str_mv | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| publishDate | 2024 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Back to the drawing board for Lykos' MDMA therapy Alison Knopf The Brown University Child & Adolescent Psychopharmacology Update Back to the drawing board for Lykos' MDMA therapy Alison Knopf The Brown University Child & Adolescent Psychopharmacology Update The Food and Drug Administration (FDA) did not accept the application of Lykos Therapeutics for MDMA as a treatment for post‐traumatic stress disorder (PTSD). In a letter dated Aug. 9 and released by Lykos Therapeutics, the for‐profit arm of the Multidisciplinary Association for Psychedelic Studies (MAPS), the company stated that it is disappointed in the FDA response, but that it intends to pursue the goal of approval. This announcement was followed by the retraction of three peer‐reviewed studies on Aug. 9 as well. The FDA did not completely reject the idea of ever approving MDMA, but asked Lykos for more information. 10.1002/cpu30905 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| title | Back to the drawing board for Lykos' MDMA therapy |
| topic | The Brown University Child & Adolescent Psychopharmacology Update |
| url | https://onlinelibrary.wiley.com/doi/10.1002/cpu30905 |